Imaging activated T cells predicts response to cancer vaccines

In situ cancer vaccines are under active clinical investigation due to their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell mediated immune response, which begins in the treated tumor and cascades systemically. We describe a positron emission tomography tracer (⁶⁴Cu-DOTA-AbOX40) that enabled non-invasive and longitudinal imaging of OX40, a cell surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide, in a dual tumor bearing mouse model. We demonstrate that OX40 imaging could predict tumor responses at day 9 post treatment based on tumor tracer uptake at day 2, with higher accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that ⁶⁴Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.

View Supplementary Materials and Methods

View Supplementary Figure 1

View Supplementary Figure 2

View Supplementary Figure 3

View Supplementary Figure 4

View Supplementary Figure 5

View Supplementary Figure 6

View Supplementary Figure 7

View Supplementary Figure 8

View Supplementary Figure 9

View Supplementary Movie 1

View Supplementary Movie 2